-
Mashup Score: 0
In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 224Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management - 29 day(s) ago
Disease Overview Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management o…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management https://t.co/l2mW3DhHM3 #leusm https://t.co/NNNGAmyOIy
-
-
Mashup Score: 81BCR::ABL1‐Positive Acute Myeloid Leukemia - 29 day(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
BCR::ABL1-Positive Acute Myeloid Leukemia https://t.co/4d9K83rCrB #leusm https://t.co/uomSlgCqtO
-
-
Mashup Score: 0
Ziftomenib elicited positive responses in patients with NPM1-mutant acute myeloid leukemia, meeting the primary end point of the phase 2 KOMET-001 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Ziftomenib demonstrated positive topline results in the registration-directed, phase 2 KOMET-001 trial for the treatment of patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. #leusm https://t.co/brJpyDitP9
-
-
Mashup Score: 59Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia - 1 month(s) ago
Key PointsDasatinib, asciminib, and prednisone can be safely combined for the dual targeting of BCR::ABL1 in Ph+ acute leukemia.Dasatinib and asciminib com
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia https://t.co/VfKxN4UEBk #leusm https://t.co/g407OsGo2U
-
-
Mashup Score: 9Improvement in cutaneous disease with menin inhibitor monotherapy in KMT2A rearranged AML - 1 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Improvement in cutaneous disease with menin inhibitor monotherapy in KMT2A rearranged AML https://t.co/uyHUZs5u0T #leusm https://t.co/KHZMJMHSQ8
-
-
Mashup Score: 36Things (like AML salvage) go better with VEN(etoclax) - 1 month(s) ago
In this issue of Blood Advances, Unglaub et al1 report a retrospective analysis in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), su
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Things (like AML salvage) go better with VEN(etoclax) https://t.co/Zn9c4FUFdc #leusm https://t.co/IexZN6Uasm
-
-
Mashup Score: 74Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML - 1 month(s) ago
Key PointsVEN plus HMA induces superior response rates in patients with R/R AML than conventional salvage therapy.The VEN plus HMA combination allows for a
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
- VEN plus HMA induces superior response rates in patients with R/R AML than conventional salvage therapy. - VEN plus HMA combination allows for a safe and effective bridging to allo-HCT. https://t.co/Zssx8Mpbt5 #leusm https://t.co/VddNzsGMTH
-
-
Mashup Score: 38The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment - 1 month(s) ago
Recent advances in acute myeloid leukemia (AML) come from studies investigating younger (age<60 years) adults or older (age≥75 years) or less fit adults
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment https://t.co/4S1Cby2P9e #leusm https://t.co/SjfK6rcaP5
-
-
Mashup Score: 5Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome - 2 month(s) ago
Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome @JenCrombieMD @DanaFarber @harvardmed @ASH_hematology#ASH24 #leusm https://t.co/4Sqa4pWodn
-
Long-Term Follow-Up of Ibrutinib/Venetoclax Provides Durable Survival in CLL/SLL | #leusm https://t.co/81zjbI426u